Merck & Company Inc (MRK)vsSera Prognostics Inc (SERA)
MRK
Merck & Company Inc
$135.84
+0.21%
HEALTHCARE · Cap: $316.14B
SERA
Sera Prognostics Inc
$1.96
-2.49%
HEALTHCARE · Cap: $75.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 115382360% more annual revenue ($65.77B vs $57,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
SERA
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.9%
Fair Value
$81.38
Current Price
$135.84
$54.46 premium
Intrinsic value data unavailable for SERA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 4.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
ROE of 7.6% — below average capital efficiency
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
SERA carries more volatility with a beta of 0.98 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?